Elanco signs agreement with Medgene to commercialize avian influenza vaccine

Elanco (ELAN) has entered into an agreement with South Dakota-based Medgene to leverage the company’s innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture’s platform technology guidelines and is in the final stages of review for conditional license approval. The USDA previously approved Medgene’s vaccine platform technology in cattle, allowing the company to accelerate H5N1 vaccine development. Medgene has existing vaccine manufacturing supply ready to deploy with the ability to support the U.S. dairy herd.